I came across this quite old article about Mr. Arun Kumar and his record with the M&A activities in past. The last para has come true to a very high degree.
One thing is quite evident that he has been quite good in identifying the future trends in the industry which seems to indicate that the Stelis BioPharma demerger & listing and the beef up injectables of Strides are steps in the right direction. With the under-recovery in SeQuent, I wish he does not repeat the mistake with Solara. We will come to know more about that in tomorrow’s call.